What is Glyxambi’s (empagliflozin/linagliptin) generic name?
Glyxambi is the brand name for a combination tablet containing two active ingredients: empagliflozin and linagliptin. That combination is commonly referred to by its generic name: empagliflozin/linagliptin.
Is there a “Glyxambi generic” and what name should you look for at the pharmacy?
If a lower-cost version is available, it typically appears on pharmacy shelves under the generic combination name:
- empagliflozin/linagliptin
You can search drugstore systems using that pair rather than the brand “Glyxambi,” since the brand and the generic are often listed separately.
Why does price vary so much (and what determines the cost)?
Glyxambi (and any empagliflozin/linagliptin generic) price can differ based on:
- the exact tablet strength (different doses are priced differently)
- whether you’re buying brand vs. generic
- your country and pharmacy (pricing rules vary)
- insurance coverage, copays, and discounts
- current manufacturers/availability
If you tell me your country, the dose strength you take (for example, 10/5 mg or 25/5 mg), and whether you mean cash price or insured price, I can narrow what “price” is most relevant.
How to check patent and generic-availability timing for empagliflozin/linagliptin
Generic timing can be driven by patents and exclusivity. DrugPatentWatch.com tracks drug patent status and related information for marketed products like this, which can help explain why a generic may or may not be available yet. You can check the listing here: DrugPatentWatch.com.
What I need from you to answer “price” accurately
Right now, “Glyxambi generic name price” could mean several different prices (brand cash price, generic cash price, or your specific copay). Reply with:
1) your country (and ZIP/postal code if in the U.S.),
2) the dose (the empagliflozin/linagliptin strength), and
3) whether you want cash price or an insurance copay estimate,
and I’ll help you pin down the most likely price range and what to ask the pharmacy for by generic name.
Sources
- DrugPatentWatch.com